TYRA Tyra Biosciences Inc

Price (delayed)

$27.14

Market cap

$1.61B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.17

Enterprise value

$1.53B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 5

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective ...

Highlights
Tyra Biosciences's equity has increased by 50% QoQ and by 20% YoY
The debt has declined by 7% year-on-year
Tyra Biosciences's quick ratio has increased by 41% from the previous quarter but it has decreased by 11% YoY
TYRA's net income is down by 36% YoY and by 9% QoQ
The EPS has declined by 33% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of TYRA

TYRA stock price

How has the Tyra Biosciences stock price performed over time
Intraday
-5.4%
1 week
-16.95%
1 month
-22.77%
1 year
164.52%
YTD
3.23%
QTD
-29.14%

Financial performance

How have Tyra Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$142.91M
Net income
-$131.11M
Gross margin
N/A
Net margin
N/A
TYRA's net income is down by 36% YoY and by 9% QoQ
The operating income has contracted by 26% YoY and by 8% from the previous quarter

Price vs fundamentals

How does TYRA's price correlate with its fundamentals

Growth

What is Tyra Biosciences's growth rate over time

Valuation

What is Tyra Biosciences stock price valuation
P/E
N/A
P/B
3.77
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 33% year-on-year and by 8% since the previous quarter
The P/B is 60% above the 5-year quarterly average of 2.5 and 5% above the last 4 quarters average of 3.8
Tyra Biosciences's equity has increased by 50% QoQ and by 20% YoY

Efficiency

How efficient is Tyra Biosciences business performance
The ROE has plunged by 55% YoY and by 3.6% from the previous quarter
The ROA has plunged by 52% YoY and by 3.6% from the previous quarter
The return on invested capital has dropped by 51% year-on-year

Dividends

What is TYRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TYRA.

Financial health

How did Tyra Biosciences financials performed over time
The total assets has grown by 46% from the previous quarter and by 20% YoY
Tyra Biosciences's quick ratio has increased by 41% from the previous quarter but it has decreased by 11% YoY
The debt is 99% smaller than the equity
The debt to equity has dropped by 50% since the previous quarter and by 50% year-on-year
Tyra Biosciences's equity has increased by 50% QoQ and by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.